MREO (Mereo BioPharma Group) EPS (Basic): $-0.25 (TTM As of Mar. 2026)


MREO Mereo BioPharma Group PLC MREO
19 GF Score
Price $0.33
! 1 Warning Sign
View Full Analysis

What is Mereo BioPharma Group EPS (Basic)?

Mereo BioPharma Group MREO +3.62% 19 EPS (Basic) is $-0.25 as of Mar. 2026. GuruFocus rates MREO with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

Mereo BioPharma Group's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.05. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.25.

Mereo BioPharma Group's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.25.

Mereo BioPharma Group's EPS without NRI for the three months ended in Mar. 2026 was $-0.06. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.24.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Mereo BioPharma Group  (NAS:MREO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Mereo BioPharma Group EPS (Basic) Related Terms

Mereo BioPharma Group EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Mereo BioPharma Group's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mereo BioPharma Group EPS (Basic) Chart

Mereo BioPharma Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 -0.35 -0.20 -0.30 -0.25

Mereo BioPharma Group Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.10 -0.05 -0.05 -0.05
MREO
19GF Score
Mereo BioPharma Group PLC MREO
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mereo BioPharma Group EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Mereo BioPharma Group's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-41.878-0)/159.424
=-0.26

Mereo BioPharma Group's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-6.719-0)/160.361
=-0.04

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.25 mean?
Mereo BioPharma Group (MREO) has a EPS (Basic) of $-0.25 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Mereo BioPharma Group and its competitors.
Is Mereo BioPharma Group's EPS (Basic) too high?
Mereo BioPharma Group's current EPS (Basic) is $-0.25. Overall, Mereo BioPharma Group has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Mereo BioPharma Group's EPS (Basic) compare to VRTX and REGN?
Mereo BioPharma Group's EPS (Basic) of $-0.25 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Mereo BioPharma Group and its competitors. Mereo BioPharma Group's current EPS (Basic) is $-0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mereo BioPharma Group stock overvalued right now?
Mereo BioPharma Group (MREO) has a current EPS (Basic) of $-0.25. The current EPS (Basic) is $-0.25. Mereo BioPharma Group's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Mereo BioPharma Group (MREO), the current EPS (Basic) is $-0.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mereo BioPharma Group Business Description

Other Exchanges 0A9G:UKMAH0:Germany
Address One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
19GF Score

Get the complete analysis for MREO

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price